Expression profiling in APP23 mouse brain: Inhibition of Aß amyloidosis and inflammation in response to LXR agonist treatment

Molecular Neurodegeneration

Volumn 2, Issue 1, 2007, Pages

  Lefterov, Iliya ^a   Bookout, Angie ^b   Wang, Zhu ^b   Staufenbiel, Matthias ^c   Mangelsdorf, David ^b   Koldamova, Radosveta ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MUS; MUS MUSCULUS; TRIFLUORO;

EID: 38749147712     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-2-20     Document Type: Article

References (57)

1. Hirsch-Reinshagen V, Wellington CL: Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, and Alzheimer's disease. Curr Opin Lipidol 2007, 18:325-332.
2. Koldamova R, Lefterov I: Role of LXR and ABCAI in the Pathogenesis of Alzheimer's Disease - Implications for a New Therapeutic Approach. Curr Alzheimer Res 2007, 4:171-178.
3. Wellington CL: Cholesterol at the crossroads: Alzheimer's disease and lipid metabolism. Clinical Genetics 2004, 66:1-16.
4. Tontonoz P, Mangelsdorf DJ: Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 2003, 17:985-993.
5. Beaven SW, Tontonoz P: Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu Rev Med 2006, 57:313-329.
6. Chinetti G, Fruchart JC, Staels B: Transcriptional regulation of macrophage cholesterol trafficking by PPARalpha and L×R. Biochem Soc Trans 2006, 34:1128-1131.
7. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P: Reciprocal regulation of inflammation and lipid metabolism by liver × receptors. Not Med 2003, 9:213-219.
8. Valledor AF, Hsu LC, Ogawa S, Sawka-Verheile D, Karin M, Glass CK: Activation of liver × receptors and retinoid × receptors prevents bacterial-induced macrophage apoptosis. Proc Natl Acad Sci U S A 2004, 101:17813-17818.
9. Zelcer N, Tontonoz P: Liver × receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006, 116:607-614.
10. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ: Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 2006, 126:789-799.
11. Oram JF, Heinecke JW: ATP-Binding Cassette Transporter AI: A Cell Cholesterol Exporter That Protects Against Cardiovascular Disease. Physiol Rev 2005, 85:1343-1372.
12. Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, McIsaac SA, Parkinson PF, Chan JY, Tansley GH, Hayden MR, Poirier J, Van NW, Wellington CL: The Absence of ABCAI Decreases Soluble ApoE Levels but Does Not Diminish Amyloid Deposition in Two Murine Models of Alzheimer Disease. J Biol Chem 2005, 280:43243-43256.
13. Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, Mclsaac SA, Chan JY, Tansley GH, Cohn JS, Hayden MR, Wellington CL: Deficiency of ABCAI Impairs Apolipoprotein E Metabolism in Brain. J Biol Chem 2004, 279:41197-41207.
14. Koldamova R, Staufenbiel M, Lefterov I: Lack of ABCAI Considerably Decreases Brain ApoE Level and Increases Amyloid Deposition in APP23 Mice. J Biol Chem 2005, 280:43224-43235.
15. Wahrle SE, Jiang H, Parsadanian M, LegleiterJ, Han X, Fryer JD, Kowalewski T, Holtzman DM: ABCAI is required for normal central nervous system ApoE levels and for lipidation of astrocytesecreted apoE. J Biol Chem 2004, 279:40987-40993.
16. Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM: Deletion of Abcal Increases Ab Deposition in the PDAPP Transgenic Mouse Model of Alzheimer Disease. J Biol Chem 2005, 280:43236-43242.
17. Brendza RP, Bales KR, Paul SM, Holtzman DM: Role of apoE/Abeta interactions in Alzheimer's disease: insights from transgenic mouse models. Mol Psychiatry 2002, 7:132-135.
18. Kim WS, Rahmanto AS, Kamili A, Rye KA, Guillemin GJ, Gelissen IC, Jessup W, Hill AF, Garner B: Role of ABCGI and ABCAI in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-beta peptide generation. J Biol Chem 2007, 282:2851-2861.
19. Burns MP, Vardanian L, Pajoohesh-Ganji A, Wang L, Cooper M, Harris DC, Duff K, Rebeck GW: The effects of ABCAI on cholesterol efflux and Abeta levels in vitro and in vivo. J Neurochem 2006.
20. Koldamova RP, Lefterov IM, Ikonomovic MD, Skoko J, Lefterov PI, lsanski BA, DeKosky ST, Lazo JS: 22R-Hydroxycholesterol and 9-cis-retinoic acid induce ABCAI transporter expression and cholesterol efflux in brain cells and decrease Ab secretion. J Biol Chem 2003, 278:13244-13256.
21. Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, Walter M, Roth MG, Lazo JS: The Liver X Receptor Ligand T0901317 Decreases Amyloid b Production in Vitro and in a Mouse Model of Alzheimer's Disease. J Biol Chem 2005, 280:4079-4088.
22. Liang Y, Lin S, Beyer TP, Zhang Y, Wu X, Bales KR, DeMattos RB, May PC, Li SD, Jiang XC, Eacho PI, Cao G, Paul SM: A liver × receptor and retinoid × receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. Journal of Neurochemistry 2004, 88:623-634.
23. Whitney KD, Watson MA, Collins JL, Benson WG, Stone TM, Numerick MJ, Tippin TK, Wilson JG, Winegar DA, Kliewer SA: Regulation of cholesterol homeostasis by the liver × receptors in the central nervous system. Mol Endocrinol 2002, 16:1378-1385.
24. Brown J III, Theisler C, Silberman S, Magnuson D, Gottardi-Littell N, Lee JM, Yager D, Crowley J, Sambamurti K, Rahman MM, Reiss AB, Eckman CB, Wolozin B: Differential Expression of Cholesterol Hydroxylases in Alzheimer's Disease. J Biol Chem 2004, 279:34674-34681.
25. Sun Y, Yao J, Kim TW, Tall AR: Expression of Liver × Receptor Target Genes Decreases Cellular Amyloid b Peptide Secretion. J Biol Chem 2003, 278:27688-27694.
26. Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, Ring RH, Kirksey Y, Aschmies S, Xu J, Kubek K, Hirst WD, Gonzales C, Chen Y, Murphy E, Leonard S, Vasylyev D, Oganesian A, Martone RL, Pangalos MN, Reinhart PH, Jacobsen JS: The L×R agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci 2007, 34:621-628.
27. Zelcer N, Khanlou N, Clare R, Jiang Q, Reed-Geaghan EG, Landreth GE, Vinters HV, Tontonoz P: Attenuation of neuroinflammation and Alzheimer's disease pathology by liver × receptors. PNAS 2007, 104:10601-10606.
28. Steffensen KR, Neo SY, Stulnig TM, Vega VB, Rahman SS, Schuster GU, Gustafsson JA, Liu ET: Genome-wide expression profiling; a panel of mouse tissues discloses novel biological functions of liver × receptors in adrenals. J Mol Endocrinol 2004, 33:609-622.
29. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM: Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Not Med 2004, 10:719-726.
30. LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE: Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem 1994, 269:23403-23406.
31. Koldamova RP, Lefterov IM, Lefterova Ml, Lazo JS: Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry 2001, 40:3553-3560.
32. Wyss-Coray T: Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Not Med 2006, 12:1005-1015.
33. Heneka MT, O'Banion MK: Inflammatory processes in Alzheimer's disease. Journal of Neuroimmunology 2007, 184:69-91.
34. Bornemann KD, Wiederhold KH, Pauli C, Ermini F, Stalder M, Schnell L, Sommer B, Jucker M, Staufenbiel M: Ab-Induced Inflammatory Processes in Microglia Cells of APP23 Transgenic Mice. Am J Pathol 2001, 158:63-73.
35. Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A, Moir RD, Domnitz SB, Frosch MP, Windisch M, Kovacs DM: The ACAT Inhibitor CP-113,818 Markedly Reduces Amyloid Pathology in a Mouse Model of Alzheimer's Disease. Neuron 2004, 44:227-238.
36. Refolo LM, Pappolla MA, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K: Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000, 7:321-331.
37. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, Tint GS, Wang R, Mercken M, Petanceska SS, Duff KE: A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2001, 8:890-899.
38. Shie FS, Jin LW, Cook DG, Leverenz JB, LeBoeuf RC: Diet-induced hypercholesterolemia enhances brain Abeta accumulation in transgenic mice. Neuroreport 2002, 13:455-459.
39. Sparks DL, Scheff SW, Hunsaker JC III, Liu H, Landers T, Gross DR: Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 1994, 126:88-94.
40. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-Traver S, Lochhead J, Ziolwolski C: Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005, 62:753-757.
41. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000, 57:1439-1443.
42. Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, Ring RH, Kirksey Y, Aschmies S, Xu J, Kubek K, Hirst WD, Gonzales C, Chen Y, Murphy E, Leonard S, Vasylyev D, Oganesian A, Martone RL, Pangalos MN, Reinhart PH, Jacobsen JS: The L×R agonist TO901317 selectively lowers hippocampal Ab 42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Molecular and Cellular Neuroscience 2007, 34:621-628.
43. Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ, Tontonoz P: L×Rs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci U S A 2001, 98:507-512.
44. Gentili C, Tutolo G, Pianezzi A, Cancedda R, scalzi Cancedda F: Cholesterol secretion and homeostasis in chondrocytes: a liver × receptor and retinoid × receptor heterodimer mediates apolipoprotein AI expression. Matrix Biology 2005, 24:35-44.
45. Haas MJ, Horani M, Mreyoud A, Plummer B, Wong NCW, Mooradian AD: Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF [alpha] and IL-I [beta]. Biochimica et Biophysica Acta (BBA) - General Subjects 2003, 1623:120-128.
46. Han CY, Chiba T, Campbell JS, Fausto N, Chaisson M, Orasanu G, Plutzky J, Chait A: Reciprocal and Coordinate Regulation of Serum Amyloid A Versus Apolipoprotein A-I and Paraoxonase-1 by Inflammation in Murine Hepatocytes. Arterioscler Thromb Vasc Biol 2006, 26:1806-1813.
47. Beyer TP, Schmidt RJ, Foxworthy P, Zhang Y, Dai J, Bensch WR, Kauffman RF, Gao H, Ryan TP, Jiang XC, Karathanasis SK, Eacho PI, Cao G: Coadministration of a liver × receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in Mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo. J Pharmacol Exp Ther 2004, 309:861-868.
48. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW: Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acod Sci U S A 2004, 101:2173-2178.
49. Rowe WB, Blalock EM, Chen KC, Kadish I, Wang D, Barrett JE, Thibault O, Porter NM, Rose GM, Landfield PW: Hippocampal expression analyses reveal selective association of immediate-early, neuroenergetic, and myelinogenic pathways with cognitive impairment in aged rats. J Neurosci 2007, 27:3098-3110.
50. Horvath AJ, Irving JA, Rossjohn J, Law RH, Bottomley SP, Quinsey NS, Pike RN, Coughlin PB, Whisstock JC: The murine orthologue of human antichymotrypsin: a structural paradigm for clade A3 serpins. J Biol Chem 2005, 280:43 168-43178.
51. Abraham CR, Selkoe DJ, Potter H: Immunochemical identification of the serine protease inhibitor alpha I-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 1988, 52:487-501.
52. Padmanabhan J, Levy M, Dickson DW, Potter H: Alphal-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. Brain 2006, 129:3020-3034.
53. Potter H, Wefes IM, Nilsson LN: The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation. Neurobiol Aging 2001, 22:923-930.
54. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B: Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A 1997, 94:13287-13292.
55. Bookout AL, Cummins CL, Mangelsdorf DJ: High-throughput realtime quantitative reverse transcription PCR. In Current Protocols in Molecular Biology Edited by: M.Ausubel, R.Brent, R.E.Kingston, D.D.Moore, J.G.Seidman, J.A.Smith and K.Struhl. Hoboken, NJ, John Willey & Sons, Inc.; 2005:15.8.
56. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang G, Shao L, DeKosky ST, Price JC, Mathis CA: Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-{beta} in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain. J Neurosci 2005, 25:10598-10606.
57. Cordle A, Landreth G: 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses. J Neurosci 2005, 25:299-307.